A Near-Complete Response to Treatment with Gemcitabine plus nab(®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report

Patients with metastatic pancreatic adenocarcinoma and poor performance status (PS) are typically excluded from clinical trials of new systemic treatments. Due to concerns that such patients cannot tolerate the greater toxicity sometimes associated with combination chemotherapy regimens, the recomme...

Descripción completa

Detalles Bibliográficos
Autor principal: Shakir, Abdur R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: October, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255998/
https://www.ncbi.nlm.nih.gov/pubmed/25493084
http://dx.doi.org/10.1159/000368346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255998/
https://www.ncbi.nlm.nih.gov/pubmed/25493084
http://dx.doi.org/10.1159/000368346

Ejemplares similares